US20050255544A1 - Lipolytic enzyme variants and method for their production - Google Patents

Lipolytic enzyme variants and method for their production Download PDF

Info

Publication number
US20050255544A1
US20050255544A1 US10/495,597 US49559704A US2005255544A1 US 20050255544 A1 US20050255544 A1 US 20050255544A1 US 49559704 A US49559704 A US 49559704A US 2005255544 A1 US2005255544 A1 US 2005255544A1
Authority
US
United States
Prior art keywords
lipolytic enzyme
amino acid
activity
variant
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/495,597
Other languages
English (en)
Inventor
Allan Svendsen
Jesper Vind
Hans Heldt-Hansen
Luise Erlandsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes AS
Original Assignee
Novozymes AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes AS filed Critical Novozymes AS
Assigned to NOVOZYMES A/S reassignment NOVOZYMES A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ERLANDSEN, LUISE, HELDT-HANSEN, HANS PETER, VIND, JESPER, SVENDSEN, ALLAN
Publication of US20050255544A1 publication Critical patent/US20050255544A1/en
Priority to US12/826,960 priority Critical patent/US9115346B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)

Definitions

  • the present invention relates to a lipolytic enzyme variant and a method of producing such a variant. More particularly, the variant has a relatively high activity for one ester bond in an amphiphilic substrate with two lipophilic groups and a relatively low activity for the ester bond in an amphiphilic substrate with one lipophilic group, e.g. a relatively high phospholipase activity and a relatively low lysophospholipase activity.
  • EP 870840, JP-A 10-42884, JP-A 4-135456 or JP-A 249593 describe the use of a phospholipase to hydrolyze a phospholipid to produce lyso-phospholipid.
  • discloses that the substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence.
  • the inventors have developed a method using protein engineering to produce lipolytic enzymes having a relatively high activity for one ester bond in an amphiphilic substrate with two lipophilic groups and a relatively low activity for the ester bond in an amphiphilic substrate with one lipophilic group, e.g. a relatively high phospholipase activity and a relatively low lysophospholipase activity.
  • the invention provides a method of producing a lipolytic enzyme variant comprising:
  • the first substrate is a molecule comprising one fatty acyl group linked through an ester or thioester bond to a hydrophilic group.
  • the second substrate is a molecule comprising a first lipophilic group which is a fatty acyl group linked through an ester or thioester bond to a hydrophilic group, and a second lipophilic group linked to the hydrophilic group, where the second lipolhilic group may be a second fatty acyl group linked through an ester, thioester or amide bond, or it may be a fatty alcohol linked through an ether or thioether bond.
  • Each amino acid alteration may be an amino acid substitution, deletion or insertion.
  • the amino acid residue to be altered may be determined from a three-dimensional model of a phospholipid docked with the parent lipolytic enzyme as a residue which comprises an atom (excluding H atoms) which lies within 10 ⁇ (particularly 7 ⁇ or 5 ⁇ ) of an atom (excluding H atoms) of the lyso-phospholipid, or it may be the C-terminal amino acid.
  • the amino acid residue to be altered may be determined by aligning the amino acid sequence of the parent lipolytic enzyme with the T. lanuginosus lipase and selecting a residue corresponding to any of residues 17-18, 20-23, 26, 37, 39, 62, 64, 80-96, 110-113, 144-151, 171-177, 200-211, 213, 215, 227, 253-261 or 263-269.
  • the invention also provides a 1. lipolytic enzyme having an amino acid sequence derived from the T. lanuginosus lipase (SEQ ID NO: 14) comprising the following amino acid alterations:
  • the invention also provides a lipolytic enzyme having an amino acid sequence derived from a Fusarium lipase comprising at least one amino acid alteration corresponding to the following in the Fusarium oxysporum lipase(phospholipase (SEQ ID NO: 7):
  • the invention provides a lipolytic enzyme which:
  • the invention uses two different polar lipids as test substrates. Both are amphiphilic (amphipolaric), having a hydrophilic part and one or two lipophilic groups, respectively.
  • the first substrate has the general formula A-B-C where:
  • the first substrate may be a lysophospholipid such as lyso-lecithin or a lyso-galactolipid such as digalactosyl monoglyceride (DGMG) or monogalactosyl monoglyceride (MGMG).
  • the lyso-phospholipid may be a 1-lyso-phospholipid with an acyl group at the sn1-position or a 2-lyso-phospholipid with an acyl group at the sn2-position.
  • the activity of interest is a hydrolytic activity towards the bond B-C.
  • the second substrate has the general formula A′-B′-(A′′-B′′-)C where:
  • A′′ and B′′ of the second substrate may be chosen identical to A and B of the second substrate and attached in the same position of C, or they may be chosen independently.
  • the second substrate may be a phospholipid such as lecithin or a galactolipid such as digalactosyl diglyceride (DGDG) or monogalactosyl diglyceride (MGDG), or it may be prepared synthetically by attaching a fatty alcohol through an ether bond or thioether bond to a lysophospholipid or a lyso-galactolipid.
  • DGDG digalactosyl diglyceride
  • MGDG monogalactosyl diglyceride
  • the activity of interest is a hydrolytic activity towards the B′-C bond.
  • the lipolytic enzyme of the invention has a low ratio of activity for the first substrate compared to activity for the second substrate. Thus, it has a relatively low hydrolytic activity towards the B-C (thio)ester bond of the first substrate and a relatively high hydrolytic activity towards the B′-C (thio)ester bond of the second substrate.
  • the activity towards the second substrate may be phospholipase A1 (EC 3.1.1.32) or A2 (EC 3.1.1.4), or it may be a galactolipase activity.
  • the activity ratio may be found by contacting the lipolytic enzyme with each substrate separately or by contacting it with a mixture including both substrates.
  • the activity ratio may be measured by the PLARN assay, the RLPLA assay or a plate assay described below.
  • the lipolytic enzyme may have a ratio of lysophospholipase activity to phospholipase activity corresponding to PLARN below 1000 (particularly 500, below 200 or below 50) or RLPLA (0.1/2.5) below 2 (particularly below 1 or below 0.5).
  • the lipolytic enzyme of the invention may have phospholipase (PL) activity with a relatively low lysophospholipase (LPL) activity.
  • the lyso-phospholipid may be a 1-lyso-phospholipid with an acyl group at the sn1-position or a 2-lyso-phospholipid with an acyl group at the sn2-position.
  • the lipolytic enzyme may in particular have phospholipase A1 activity with low 1-lysophospholipase activity.
  • the lipolytic enzyme of the invention may have hydrolytic activity towards a carboxylic ester bond in DGDG (digalactosyl diglyceride) with a relatively low hydrolytic activity towards the ester bond in DGMG (digalactosyl monoglyceride).
  • DGDG digalactosyl diglyceride
  • DGMG digalactosyl monoglyceride
  • the lipolytic enzyme may also have triacylglycerol lipase activity (EC 3.1.1.3), i.e. hydrolytic activity for carboxylic ester bonds in triglycerides, e.g. 1,3-specific activity, particularly on long-chain triglycerides such as olive oil.
  • the enzyme may have a substrate specificity for hydrolyzing long-chain fatty acyl groups rather than short-chain groups, e.g. expressed as a high ratio of activities on olive oil and tributyrin, e.g. a ratio SLU/LU>3 as described in WO 0032758.
  • Phospholipase activity is determined at 30° C. using 4% (w/v) lecithin (phosphatidyl choline) in 50 mM sodium acetate, 5 mM CaCl2, pH 5.0.
  • lecithin phosphatidyl choline
  • One unit of phospholipase activity is defined as 1 mmol free fatty acids released per minute per mg enzyme using the above conditions.
  • Lysophospholipase activity is determined at 30° C. using 1% (w/v) lysolechitin in 50 mM sodium acetate, 5 mM CaCl2, pH 5.0.
  • One unit of lysophospholipase activity is defined as 1 mmol free fatty acids released per minute per mg enzyme using the above conditions.
  • the lysolechitin may be an equilibrium mixture or pure 1-lysolechitin in the case of a phospholipase A1 and pure 2-lysolechitin in the case of a phospholipase A2.
  • the PLARN ratio is defined as the lysophospholipase activity divided by the phospholipase activity, both determined by the above methods.
  • This activity measurement expresses the relative activity on lysophosphatidyl choline and phosphatidyl choline in an equimolar mixture.
  • the assay is carried out as follows: The activity at different concentrations of phospholipase is determined at 30° C. blending 1:1 solutions of phosphatidyl choline (25 mM) and lysophosphatidyl choline (25 mM) in 50 mM NaOAc buffer (pH 5). 50 ⁇ l enzyme solution (e.g. having 0.1 or 2.5 mg enzyme protein per ml) is added to the substrate solution and allowed to react for 30 minutes. 100 ⁇ l of the sample is inactivated at 95° C. for 5 minutes and dissolved in 900 ⁇ l CHCl3/MeOH 50%/50%. The sample is centrifuged at 14000 rpm for 2 minutes.
  • 50 ⁇ l enzyme solution e.g. having 0.1 or 2.5 mg enzyme protein per ml
  • the supernatant is analyzed by HPLC after filtering through a 0.45 ⁇ m filter.
  • the RLPLA is then measured as the depletion of phosphatidyl choline relative to lysophosphatidyl choline.
  • a variant with a lower RLPLA value indicates a higher accumulation of lysophospholipid under the conditions of analysis.
  • the relative activity can be expressed as “RLPLA ratio” by measuring lysolecithin hydrolysis at an enzyme dosage of 0.1 mg/ml and lecithin hydrolysis at a dosage of 2.5 mg/ml, and taking the ratio of the two.
  • Plates including each of the substrates may be prepared in analogy with WO 0032758 using suitable pH and substrate concentration.
  • other ingredients such as flour may be included.
  • a suitably diluted enzyme solution is applied to holes in the plates, and clearing zones are read after incubation for a suitable time at a suitable temperature.
  • the lipolytic enzyme may be obtained by preparing variants of a parent lipolytic enzyme by altering its amino acid sequence and screening for a variant with an improved activity ratio.
  • the parent lipolytic enzyme may have phospholipase activity, DGDG hydrolytic activity and/or triacylglycerol lipase activity.
  • Variants may be prepared from the parent lipolytic enzyme by known methods, e.g. by subjecting a DNA sequence encoding the parent lipolytic enzyme to site-directed mutagenesis, localized random mutagenesis or site-saturation mutagenesis, e.g. using methods described in WO 0032758. Resulting DNA sequences may be further modified by gene shuffling and directed evolution.
  • the lipolytic enzyme to be used in the present invention is one that can hydrolyze ester bonds.
  • Such enzymes include, for example, lipases, such as triacylglycerol lipase (EC 3.1.1.3), lipoprotein lipase (EC 3.1.1.34), monoglyceride lipase (EC 3.1.1.23), phospholipase A1 or A2 (EC 3.1.1.26, 3.1.1.4), lysophospholipase (EC 3.1.1.5), galactolipase (EC 3.1.1.26), ferulic acid esterase and esterase (EC 3.1.1.1, EC 3.1.1.2).
  • lipases such as triacylglycerol lipase (EC 3.1.1.3), lipoprotein lipase (EC 3.1.1.34), monoglyceride lipase (EC 3.1.1.23), phospholipase A1 or A2 (EC 3.1.1.26, 3.1.1.4), lysophospholipase (EC 3.1.
  • the parent lipolytic enzyme may be the Thermomyces lanuginosus lipase ( Humicola lanuginosa lipase) (EP 305216) or it may have an amino acid sequence with at least 50% identity (e.g. at least 90% identity).
  • the amino acid sequence of the T. lanuginosus lipase is shown in U.S. Pat. No. 5,869,438 and as seq 14 in FIG. 2 of this application.
  • the parent lipolytic enzyme may be a naturally occurring enzyme as described at pages 5-6 of WO 0032758.
  • Examples are the lipolytic enzymes from the following organisms. They are known in the prior art; and their amino acid sequences are given in the attached sequence listing.
  • the amino acid to be altered may be determined on the basis of an alignment of the parent lipolytic enzyme with the T. lanuginosus lipase.
  • FIG. 2 shows an alignment of the amino acid sequences of the above fungal lipolytic enzymes, based on a comparison of the available 3-dimensional structures:
  • GAP amino acid sequence alignment
  • GAP is provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wis., USA 53711) (Needleman, S. B. and Wunsch, C. D., (1970), Journal of Molecular Biology, 48, 443-45). The following settings are used for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1.
  • the parent lipolytic used in the present invention may be a variant of the above, e.g. a variant of the T. lanuginosus lipase (SEQ ID NO: 14) or the F. oxysporum lipase/phospholipase (SEQ ID NO: 7).
  • a variant with phospholipase activity or galactolipase activity may be used, e.g. as described in Example 5, 6 or 13 of WO 0032758.
  • SEQ ID NO: 14 Particular examples are variants of SEQ ID NO: 14 with the following amino acid alterations: L259S G266D G91A + D96W + E99K + G263Q + L264A + I265T + G266D + T267A + L269N + 270A + 271G + 272G + 273F + 274S G266E G263A + G266A E1SPCRPRP + E239C + Q249R + G266A E1SPCRPRP + E239C + Q249R + G266S D96S + G266A D96S + G266S D96S + G266W E1SPPCGRRP + D96S + E239C + Q249R + G263D + L264I + I265N + G266E + T267GS Three-Dimensional Model
  • FIG. 1 gives the coordinates of a three-dimensional model of the T. lanuginosus lipase docked with a phospholipid as substrate: 1-palmetoyl-2-oleylglycero-sn-3-phosphocholine (POPC). This may be used as a starting point for building a similar model for any given fungal lipolytic enzyme. Using this model, the following amino acid residues are found to be within 10 ⁇ , 7 ⁇ and 5 ⁇ of an atom of the substrate (LIP1 in the pdb structure shown in FIG. 1 ):
  • amino acid alterations may be made at one or more positions corresponding to the following amino acids in the T. lanuginosus lipase (SEQ ID NO: 14): Y212, R84, S85, E87, D96, V203, L206, L227, P253, D254, P256, P257 and/or Y261, particularly one or more alterations corresponding to Y21V/K, R84W/A/G/Y/S, S85D, E87A, D96F/K/G, V203I, L206F, P253Q, D254*, P256N, P257S and/or Y261Q.
  • amino acid alterations may be made at one or more positions corresponding to H257, S142, S80, D263 and/or Y21 of the F. oxysporum lipase/phospholipase (SEQ ID NO: 7), particularly one or more corresponding to H257W, S142A, S80T, D263G and/or Y21W.
  • amino acid alterations may be made at the C-terminal or at any position downstream of L269 of SEQ ID NO: 14. Such alteration may be addition or deletion of a peptide extension or deletion of a peptide extension of one or more amino acids (e.g. 1-50 amino acids such as 2-15) at the C-terminal.
  • the amino acid alteration may be substitution with a larger amino acid.
  • the amino acid residues are ranked by size as follows from smallest to largest:
  • amino acid residue within 10 ⁇ (or 7 ⁇ or 5 ⁇ ) of a C atom in the alkyl group R of R—COO attached to sn1 of the lyso-phospholipid may be substituted with an amino acid residue which is larger or more hydrophilic.
  • amino acid residue within 10 ⁇ (or 7 ⁇ or 5 ⁇ ) of an atom (other than H) of the phosphate group attached to sn3 may be substituted with an amino acid which is larger or more hydrophobic.
  • Amino acid residues are ranked as follows from most hydrophilic to most hydrophobic:
  • One concept is to lower the binding energy of sn1 acyl chain and in this way increase the ratio of activity lecithin/lysolecithin(sn1). Secondary to increase sn2 binding to favour lecithin rather than lysolecithin.
  • 206, 95, 203 and 93 may be made smaller and more hydrophilic. Also, positions 253, 255 and 256 may be made bigger.
  • a doped library 206/203 and 95/93. appr. 90% wt and appr 10% variant may be used.
  • a second concept is to make libraries in the contacts to both acyl chains found docked structures, and in the regions close to the substrate found by comparison of good and bad lysolecithase active homologous enzymes.
  • the regions will be doped according to the homologous enzymes sequence.
  • region 265-269 is of interest, e.g. P253.
  • Some particular examples of such variants are:
  • a doped library 247-260 may be used, optionally together with doped 1202P and L206V.
  • the doping may be appr 90% wt and appr. 10% variants.
  • the lipolytic enzyme of the invention and the parent lipolytic enzyme may have an amino acid identity of at least 50% (particularly at least 90%, e.g. more than 95% or more than 98%) with the T. lanuginosus lipase (SEQ ID NO: 14).
  • the degree of identity may be suitably determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wis., USA 53711) (Needleman, S. B. and Wunsch, C. D., (1970), Journal of Molecular Biology, 48, 44345), using GAP with the following settings for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1.
  • a variant with phospholipase activity can be used to prepare lysophospholipid (e.g. lyso-lecithin) by treating the corresponding phospholipid with the variant, e.g. as described in EP 870840, JP-A 10-42884, JP-A 4-135456 or JP-A 2-49593.
  • the variant can also be used to make mayonnaise, e.g. as described in EP 628256, EP 398666 or EP 319064.
  • a low ratio of lysophospholipase/phospholipase activity can lead to a high degree of phospholipid hydrolysis with a low degree of lysophospholipid hydrolysis. This may allow the use of long reaction time and the use of phospholipid with a high lyso-phospholipid content, e.g. from cereals such as oats.
  • Lipolytic enzymes according to the invention have improved baking performance, e.g. a lower dough stickiness, a better dough extensibility and elasticity, a better dough stability, a better crumb structure of the baked product, a larger loaf volume and/or improved resistance to over-proofing or other abuse.
  • the invention provides a baking additive in the form of a granulate, an agglomerated powder or a stabilized liquid, comprising a lipolytic enzyme which:
  • the baking additive may have a narrow particle size distribution with more than 95% (by weight) of the particles in the range from 25 to 500 ⁇ m.
  • Granulates and agglomerated powders may be prepared by conventional methods, e.g. by spraying the lipolytic enzyme onto a carrier in a fluid-bed granulator.
  • the carrier may consist of particulate cores having a suitable particle size.
  • the carrier may be soluble or insoluble, e.g. a salt (such as NaCl or sodium sulfate), a sugar (such as sucrose or lactose), a sugar alcohol (such as sorbitol), starch, rice, corn grits, or soy.
  • Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods.
  • the invention further relates to a pre-mix comprising flour and the lipolytic enzyme described above.
  • the pre-mix may contain other dough-improving and/or bread-improving additives, e.g. any of the additives, including enzymes, mentioned above.
  • the invention also provides a method of preparing a dough or a baked product prepared from dough.
  • the method may comprise preparing a variant by the above method and adding it to the dough.
  • the method may comprise:
  • the dough generally comprises wheat meal or wheat flour and/or other types of meal, flour or starch such as corn flour, corn starch, rye meal, rye flour, oat flour, oat meal, soy flour, sorghum meal, sorghum flour, rice starch, rice flour, potato meal, potato flour or potato starch.
  • the dough may be fresh, frozen or par-baked. It may particularly be a leavened dough.
  • the dough may also comprise other conventional dough ingredients, e.g.: proteins, such as milk powder, gluten, and soy; eggs (either whole eggs, egg yolks or egg whites); an oxidant such as ascorbic acid, potassium bromate, potassium iodate, azodicarbonamide (ADA) or ammonium persulfate; an amino acid such as L-cysteine; a sugar; a salt such as sodium chloride, calcium acetate, sodium sulfate or calcium sulfate.
  • proteins such as milk powder, gluten, and soy
  • eggs either whole eggs, egg yolks or egg whites
  • an oxidant such as ascorbic acid, potassium bromate, potassium iodate, azodicarbonamide (ADA) or ammonium persulfate
  • an amino acid such as L-cysteine
  • a sugar a salt such as sodium chloride, calcium acetate, sodium sulfate or calcium sulfate.
  • the dough may comprise fat (triglyceride) such as granulated fat or shortening, but the invention is particularly applicable to a dough where less than 1% by weight of fat (triglyceride) is added, and particularly to a dough which is made without addition of fat.
  • fat triglyceride
  • the dough may further comprise an emulsifier such as mono- or diglycerides, diacetyl tartaric acid esters of mono- or diglycerides, sugar esters of fatty acids, polyglycerol esters of fatty acids, lactic acid esters of monoglycerides, acetic acid esters of monoglycerides, polyoxyethylene stearates, or lysolecithin, but the invention is particularly applicable to a dough which is made without addition of emulsifiers (other than optionally phospholipid).
  • an emulsifier such as mono- or diglycerides, diacetyl tartaric acid esters of mono- or diglycerides, sugar esters of fatty acids, polyglycerol esters of fatty acids, lactic acid esters of monoglycerides, acetic acid esters of monoglycerides, polyoxyethylene stearates, or lysolecithin
  • the process of the invention may be used for any kind of baked product prepared from dough, either of a soft or a crisp character, either of a white, light or dark type.
  • Examples are bread (in particular white, whole-meal or rye bread), typically in the form of loaves or rolls, French baguette-type bread, pita bread, tortillas, cakes, pancakes, biscuits, cookies, muffins, pie crusts, crisp bread, steamed bread, pizza and the like.
  • an additional enzyme may be used together with the lipolytic enzyme.
  • the additional enzyme may be a second lipolytic enzyme (e.g. as described in PCT/DK01/00472), an amylase, particularly an anti-staling amylase, an amyloglucosidase, a cyclodextrin glucanotransferase, or the additional enzyme may be a peptidase, in particular an exopeptidase, a transglutaminase, a cellulase, a hemicellulase, in particular a pentosanase such as xylanase, a protease, a protein disulfide isomerase, e.g., a protein disulfide isomerase as disclosed in WO 95/00636, a glycosyltransferase, a branching enzyme (1,4- ⁇ -glucan branching enzyme), a 4- ⁇ -glucanotransferase (d
  • the amylase may be a fungal or bacterial alpha-amylase, e.g. from Bacillus , particularly B. licheniformis or B. amyloliquefaciens , or from Aspergillus , particularly A. oryzae , a betaamylase, e.g. from plant (e.g. soy bean) or from microbial sources (e.g. Bacillus ).
  • the amylase may be an anti-staling amylase, as described in WO 99/53769, i.e. an amylase that is effective in retarding the staling (crumb firming) of baked products, particularly a maltogenic alpha-amylase, e.g. from Bacillus stearothermophilus strain NCIB 11837.
  • the lipolytic enzyme variant may also be used in the production of pasta and noodles in analogy with EP 1057415.
  • a lipolytic enzyme variant with phospholipase activity may be used in cheese production as described in WO 00/54601.
  • a prior-art variant of the T. lanuginosus lipase with phospholipase activity was chosen as the starting point (parent lipolytic enzyme), and variants were prepared by introducing further amino acid alterations into the prior-art variant.
  • Activities of the new variants were determined with lecithin and lysolecithin (pure 1-phosphatidyl choline, 1-lysolecithin) as substrates by the methods described above. More specifically, 1.7 mL of the reaction mixture was shaken for between 15 and 90 min in an Eppendorf tube shaken at 1300 rpm by an “Eppendorf Thermomixer comfort”. The enzyme was inactivated at 95 C for 5 min, and centrifuged at 14000 rpm by Eppendorf centrifuge 5417R. The liberated fatty acids were determined (relative to a control sample where the enzyme was inactivated before it was added to the substrate) by NEFA C test from Wako following the ACS-ACOD method described for the NEFA-C test.
  • Variants of the F. oxysporum lipase/phospholipase were prepared, having the following amino acid alterations compared to SEQ ID NO: 7:
  • Doughs were prepared from Meneba flour according to the European straight dough method (ABF-SP 1201.1) with 40 ppm Fungamyl Super MA (Novozymes), 40 ppm ascorbic acid, and different dosages of lipolytic enzyme.
  • the stickiness of the dough was evaluated an a 1-10 scale by the baker as the degree to which a dough adheres to ones hands or other surfaces, where 5 is identical to a control without addition of lipolytic enzyme, 1 is the lowest degree of stickiness and 10 is the highest degree of stickiness.
  • the extensibility of the dough was evaluated an a 1-10 scale by the baker as the degree to which a dough can be stretched without tearing, where 5 is identical to a control without addition of lipolytic enzyme, 1 indicates the lowest (shortest) extensibility and 10 indicates the highest (longest) extensibility
  • the elasticity of the dough was evaluated an a 1-10 scale by the baker as the degree to which a dough tends to recover its original shape after release from a deforming force, where 5 is identical to a control without addition of lipolytic enzyme, 1 indicates the lowest (weakest) elasticity and 10 indicates the highest (strongest) elasticity.
  • Example 1 A lipolytic enzymes prepared in Example 1 was tested, and the prior-art variant was tested for comparison. The results were as follows Experiment A Lipolytic PLARN Sticki- Extensi- Elasti- enzyme Dosage ratio ness bility city Invention 0.2 mg/kg dough 690 5 6 4 Prior art 250 LU/kg dough 5800 5 7 3
  • lipolytic enzymes with a lower ratio of lysolecithin activity to lecithin activity make doughs with a desirable combination of lower extensibility and higher elasticity than the prior-art lipolytic enzymes, and they furthermore tend to make a less sticky dough.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
US10/495,597 2002-01-16 2003-01-16 Lipolytic enzyme variants and method for their production Abandoned US20050255544A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/826,960 US9115346B2 (en) 2002-01-16 2010-06-30 Lipolytic enzymes

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200074 2002-01-16
DKPA200200074 2002-01-16
PCT/DK2003/000028 WO2003060112A1 (en) 2002-01-16 2003-01-16 Lipolytic enzyme variants and method for their production

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/826,960 Continuation US9115346B2 (en) 2002-01-16 2010-06-30 Lipolytic enzymes

Publications (1)

Publication Number Publication Date
US20050255544A1 true US20050255544A1 (en) 2005-11-17

Family

ID=8161014

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/495,597 Abandoned US20050255544A1 (en) 2002-01-16 2003-01-16 Lipolytic enzyme variants and method for their production
US12/826,960 Expired - Fee Related US9115346B2 (en) 2002-01-16 2010-06-30 Lipolytic enzymes

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/826,960 Expired - Fee Related US9115346B2 (en) 2002-01-16 2010-06-30 Lipolytic enzymes

Country Status (6)

Country Link
US (2) US20050255544A1 (de)
EP (2) EP1468084A1 (de)
AU (1) AU2003203139B2 (de)
CA (1) CA2467415C (de)
DK (1) DK2295556T3 (de)
WO (1) WO2003060112A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100286258A1 (en) * 2007-05-24 2010-11-11 Krishnadath Bhaggan Process

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936289B2 (en) 1995-06-07 2005-08-30 Danisco A/S Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
CA2366843A1 (en) * 1999-03-31 2000-10-12 Jesper Vind Lipase variant
DK1387616T3 (da) 2001-05-18 2007-09-24 Danisco Fremgangsmåde til fremstilling af en dej med et enzym
EP2278015B1 (de) 2003-01-17 2014-08-13 DuPont Nutrition Biosciences ApS Verfahren zur Herstellung eines Kohlenhydratesters
EP2270139B1 (de) * 2003-05-09 2016-07-27 Novozymes A/S Varianten lipolytischer enzyme
US7754460B2 (en) * 2003-12-03 2010-07-13 Danisco Us Inc. Enzyme for the production of long chain peracid
JP5604032B2 (ja) 2004-07-16 2014-10-08 デュポン ニュートリション バイオサイエンシーズ エーピーエス 食用油の酵素的脱ガム方法
EP2298872A3 (de) 2004-09-30 2011-08-10 Novozymes A/S Polypeptide mit Lipase-Aktivität und diese kodierende Polynukleotide
EP1976967A2 (de) 2006-01-23 2008-10-08 The Procter and Gamble Company Waschmittelzusammensetzungen
EP1987158A2 (de) * 2006-02-06 2008-11-05 Novozymes A/S Screening-verfahren zur auswahl von lipolyseenzymen zur verbesserung von backwaren
DE102006046719A1 (de) 2006-10-02 2008-04-03 Ab Enzymes Gmbh Klonierung, Expression und Verwendung saurer Phospholipasen
DE102006046857A1 (de) 2006-10-02 2008-04-03 Ab Enzymes Gmbh Klonierung, Expression und Verwendung saurer Lysophospholipasen
US8273348B2 (en) * 2006-12-21 2012-09-25 Novozymes A/S Lipase variants for pharmaceutical use
DE102009051013A1 (de) 2009-10-28 2011-06-09 Ab Enzymes Gmbh Klonierung, Expression und Verwendung saurer Phospholipasen
ES2546630T3 (es) 2012-01-30 2015-09-25 Dsm Ip Assets B.V. Alfa-amilasa
WO2013113622A1 (en) * 2012-02-03 2013-08-08 Novozymes A/S Lipase variants and polynucleotides encoding same
KR20150067336A (ko) * 2012-10-12 2015-06-17 다니스코 유에스 인크. 지방분해 효소 변이체를 포함하는 조성물 및 방법
BE1022042B1 (nl) 2014-09-29 2016-02-08 Puratos Nv Verbeterde cakebeslagsoorten
EP3280818A2 (de) 2015-04-07 2018-02-14 Novozymes A/S Verfahren zur selektion von enzymen mit lipase-aktivität
CN110129298B (zh) * 2016-06-02 2021-08-03 天津科技大学 一种磷脂酶d突变体及其应用
EP3559222A1 (de) 2016-12-21 2019-10-30 DSM IP Assets B.V. Varianten lipolytischer enzyme
MX2019007375A (es) 2016-12-21 2019-09-18 Dsm Ip Assets Bv Variante de enzima lipolitica.
WO2018114938A1 (en) 2016-12-21 2018-06-28 Dsm Ip Assets B.V. Lipolytic enzyme variants
WO2018114912A1 (en) 2016-12-21 2018-06-28 Dsm Ip Assets B.V. Lipolytic enzyme variants
AU2018387151B2 (en) 2017-12-19 2024-05-02 International N&H Denmark Aps Improved enzymatic modification of phospholipids in food
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
WO2023222614A1 (en) * 2022-05-16 2023-11-23 Dsm Ip Assets B.V. Lipolytic enzyme variants

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3368903A (en) * 1966-02-18 1968-02-13 Vanderbilt Co R T Baked goods dough and method
US4567046A (en) * 1982-11-10 1986-01-28 Kyowa Hakko Kogyo Co., Ltd. Bread or other cereal-based food improver composition involving the addition of phospholipase A to the flour
US5352594A (en) * 1984-05-29 1994-10-04 Genecor, Inc. Selection and method of making enzymes for perhydrolysis system and for altering substrate specificity, specific activity and catalytic efficiency
US6265197B1 (en) * 1998-07-02 2001-07-24 Novozymes A/S Krogshoejvej Starch debranching enzymes
US7312062B2 (en) * 1998-11-27 2007-12-25 Novozymes A/S Lipolytic enzyme variants

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221627A (en) 1986-09-09 1993-04-28 Genencor Inc Preparation of enzymes, modifications, catalytic triads to alter ratios or transesterification/hydrolysis ratios
JPS644288A (en) 1987-06-25 1989-01-09 Nippon Electric Kagoshima Ltd Preparation of pure water
EP0305216B1 (de) 1987-08-28 1995-08-02 Novo Nordisk A/S Rekombinante Humicola-Lipase und Verfahren zur Herstellung von rekombinanten Humicola-Lipasen
ES2032000T3 (es) 1987-12-03 1993-01-01 Unilever Nv Un procedimiento para la preparacion de una emulsion de agua y aceite.
JP2794574B2 (ja) 1988-08-11 1998-09-10 昭和産業株式会社 リゾレシチンの製造方法
JP2877439B2 (ja) 1989-05-17 1999-03-31 協和醗酵工業株式会社 卵の改質方法
DK46693D0 (de) * 1993-04-23 1993-04-23 Novo Nordisk As
US5869438A (en) 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
CA2092615A1 (en) 1990-09-13 1992-03-14 Allan Svendsen Lipase variants
US5892013A (en) 1990-09-13 1999-04-06 Novo Nordisk A/S Lipase variants
JPH0687751B2 (ja) 1990-09-26 1994-11-09 辻製油株式会社 高濃度のリゾホスファチジルコリンを含むリゾレシチンを採取する方法
GB9114734D0 (en) 1991-07-09 1991-08-28 Univ London Process for modifying proteins
TW362115B (en) 1992-06-16 1999-06-21 Sankyo Lifetech Co Ltd Novel phospholipase A1, process for its preparation and the use thereof
EP0585988B1 (de) 1992-07-27 1996-03-13 Gist-Brocades N.V. Enzymprodukt und Verfahren zur Verbesserung der Qualität von Brot
GB9216387D0 (en) 1992-07-31 1992-09-16 Unilever Plc Enzymatic detergent compositions
DK104592D0 (da) 1992-08-21 1992-08-21 Novo Nordisk As Fremgangsmaade
JPH06113845A (ja) 1992-10-06 1994-04-26 Asahi Chem Ind Co Ltd 高モノグリセリド分解性を有する改良リパーゼ及びその製造法
AU5700094A (en) 1992-12-23 1994-07-19 Unilever N.V. Modified cutinases, dna, vector and host
EP0628256B1 (de) 1993-06-11 1997-08-13 Societe Des Produits Nestle S.A. Zusammensetzung für Wärmestabilisierung von Proteinen und Produkt daraus
DK76893D0 (de) 1993-06-28 1993-06-28 Novo Nordisk As
DE69632538T2 (de) 1995-08-11 2005-05-19 Novozymes A/S Neuartige lipolytische enzyme
JP3791058B2 (ja) 1996-07-30 2006-06-28 日本油脂株式会社 リゾレシチンの製造方法
AU739267B2 (en) 1996-09-30 2001-10-11 Genencor International, Inc. Esterases, DNA encoding therefor and vectors and host cells incorporating same
US6103505A (en) 1996-12-09 2000-08-15 Novo Nordisk A/S Method for reducing phosphorus content of edible oils
AR010340A1 (es) 1996-12-09 2000-06-07 Novozymes As COMPOSICIoN PARA HORNEADO, USO DE DICHA COMPOSICIoN Y USO DEL POLIPÉPTIDO DE DICHA COMPOSICIoN.
DE19701348A1 (de) 1997-01-16 1998-07-23 Roehm Gmbh Protein mit Phospholipaseaktivität
US5821102A (en) 1997-01-21 1998-10-13 Novo Nordisk Biotech Inc. Nucleic acids encoding polyeptides having absidia lipase activity
JP3853464B2 (ja) 1997-04-08 2006-12-06 辻製油株式会社 植物性リゾレシチンの製造法
DK0973399T3 (da) 1997-04-09 2002-11-11 Danisco Forbedret fremgangsmåde til fremstilling af meldeje og produkter fremstillet af sådanne deje under anvendelse af glyceroloxidase
DK1073339T4 (da) 1998-04-20 2008-08-18 Novozymes As Fremstilling af dej og bagte produkter
EP2716753A1 (de) * 1998-11-27 2014-04-09 Novozymes A/S Varianten eines lipolytischen Enzyms
DK1131416T3 (da) 1998-11-27 2009-10-26 Novozymes As Lipolytiske enzymvarianter
ATE289482T1 (de) 1999-03-16 2005-03-15 Novozymes As Verfahren zur herstellung von käse
EP1057415A1 (de) 1999-06-04 2000-12-06 Societe Des Produits Nestle S.A. Mit Lipase behandelte Teigware und Verfahren ihrer Herstellung
AU6790600A (en) * 1999-09-03 2001-04-10 Procter & Gamble Company, The Detergent composition having granular cyclodextrin
US6146869A (en) 1999-10-21 2000-11-14 Novo Nordisk Biotech, Inc. Polypeptides having phospholipase B activity and nucleic acids encoding same
EP1108360A1 (de) 1999-12-03 2001-06-20 Danisco A/S Verfahren zur Verbesserung der Qualität von Teig und Brot
US20020192792A1 (en) 2000-04-28 2002-12-19 Palle Schneider Laccase mutants
EP2281878A1 (de) 2000-06-26 2011-02-09 Novozymes A/S Lipolytisches Enzym

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3368903A (en) * 1966-02-18 1968-02-13 Vanderbilt Co R T Baked goods dough and method
US4567046A (en) * 1982-11-10 1986-01-28 Kyowa Hakko Kogyo Co., Ltd. Bread or other cereal-based food improver composition involving the addition of phospholipase A to the flour
US5352594A (en) * 1984-05-29 1994-10-04 Genecor, Inc. Selection and method of making enzymes for perhydrolysis system and for altering substrate specificity, specific activity and catalytic efficiency
US6265197B1 (en) * 1998-07-02 2001-07-24 Novozymes A/S Krogshoejvej Starch debranching enzymes
US7312062B2 (en) * 1998-11-27 2007-12-25 Novozymes A/S Lipolytic enzyme variants
US20080131951A1 (en) * 1998-11-27 2008-06-05 Novozymes A/S Lipolytic Enzyme Variants
US20090047384A1 (en) * 1998-11-27 2009-02-19 Novozymes A/S Lipolytic enzyme variants

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100286258A1 (en) * 2007-05-24 2010-11-11 Krishnadath Bhaggan Process
US8673967B2 (en) * 2007-05-24 2014-03-18 Loders Croklaan B.V. Process

Also Published As

Publication number Publication date
CA2467415A1 (en) 2003-07-24
EP1468084A1 (de) 2004-10-20
AU2003203139A1 (en) 2003-07-30
EP2295556A2 (de) 2011-03-16
DK2295556T3 (en) 2015-01-26
EP2295556A3 (de) 2011-06-29
CA2467415C (en) 2014-03-11
US9115346B2 (en) 2015-08-25
WO2003060112A1 (en) 2003-07-24
EP2295556B1 (de) 2014-10-29
US20110165655A1 (en) 2011-07-07
AU2003203139B2 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
US9115346B2 (en) Lipolytic enzymes
US8298800B2 (en) Lipolytic enzyme variants
US9247753B2 (en) Preparation of dough or baked products
US8916368B2 (en) Lipases and uses thereof
AU2008200576A1 (en) Lipolytic enzyme variants and method for their production
CA2412533C (en) Method of preparing a dough or a baked product made from a dough, with addition of lipolytic enzymes
AU2001272359A1 (en) Method of preparing a dough or a baked product made from a dough, with addition of lipolytic enzymes
US20130045302A1 (en) Screening Method

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVOZYMES A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SVENDSEN, ALLAN;VIND, JESPER;HELDT-HANSEN, HANS PETER;AND OTHERS;REEL/FRAME:016046/0043;SIGNING DATES FROM 20040425 TO 20040429

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION